Company Profile
VBI Vaccines Stock Price, News & Analysis
Company overview
Business overview
VBI Vaccines is an infectious-disease or vaccine company focused on immunity-driven programs where clinical, regulatory, and demand cycles can shift quickly.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, VBI Vaccines is followed within the infectious-disease universe for its exposure to vaccine and antiviral catalysts.
Business Model Characteristics
VBI Vaccines combines program development with demand-sensitive launch execution, so investors usually track efficacy, safety, and the commercial path for each major asset.
Position Within the Biotechnology Landscape
Compared with broader biotech peers, VBI Vaccines sits in a catalyst-heavy corner of the landscape where virus, vaccine, and antiviral updates can move sentiment quickly.
Why the stock is moving
VBIV is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
VBI Vaccines is likely to be watched for earnings, launch execution, reimbursement, and guidance over the next three months around infectious disease and vaccine.
Investors will also pay attention to clinical readouts, regulatory milestones, and commercial execution because those updates can show whether the business is turning product momentum into a steadier operating profile.
If management adds clearer commentary on infectious disease and vaccine, the market can reframe the next catalyst window very quickly.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.